Table 2.

Clinical trials with antioxidants in neurological injury.

Antioxidants	Route	Disease Patients	Dosage	Follow Up Period	No. of Patients	Outcome	References
Resveratrol	Oral/ Infusion	Stroke	2.5 mg/kg	0–2 h of stroke onset	312	Decreased MMP-9 and MMP-2 levels	[253,254]
EGCG	Intravenous/ oral/ infusion	Stroke	500 mg	0–5 h of stroke onset	371	Decreased MMP-9 and MMP-2 levels	[255]
Edaravone	Intravenous	Stroke	30 mg 60 mg	6 months 12–24 h of stroke onset	40163	Effective recovery Decreased MMP-9 levels	[264,265]
Edaravone Dexborneol	Intravenous	Stroke Intracerebral Hemorrhage	12.5 mg, 37.5 mg or 62.5 mg every 12 h for 14 days 37.5 mg every 12 h for 14 days	3 months NA	385390 (estimated)	Safe and well tolerated No Recruitment	[266,267]
Nanoparticle-loaded Edaravone	Intravenous	Cerebral Hemorrhage	25 mg	3 weeks	120	Reduced edema Improved neurological function Reduced interleukin and tumor necrosis factor	[275]
Ginkgo biloba and, Aspirin	Oral	Stroke	450 mg 100 mg	6 months	348	Alleviated cognitive and neurological impairment	[276]
Omega-3 pill Vegetation Protein Powder InflanNox (curcumin) capsuleAnti-oxidant Network capsule Chlorella tablet	Oral	SCI	500 mg/d EPA, 250 mg/d DHA, thrice 45 g/d 400 mg/d thrice 615 mg/d twice 1000 mg/d, 6 times	3 months	20	Improvement in behavior Modification in neuroactive compounds Reduction in IL-1β	[277]